BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//swoogo.com//NONSGML kigkonsult.se iCalcreator 2.41.90//
CALSCALE:GREGORIAN
UID:30363232-3934-4366-b436-386361336432
BEGIN:VEVENT
UID:3e678e84e828e1f61866db8288c66961805d3670@swoogo.com
DTSTAMP:20260905T021254Z
DESCRIPTION:This presentation discusses perioperative IMFINZI (durvalumab) 
 in combination with FLOT (fluorouracil\, leucovorin\, oxaliplatin and doce
 taxel)\, followed by adjuvant IMFINZI alone\, for the treatment of resecta
 ble gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)\, along 
 with IMFINZI + IMJUDO (tremelimumab-actl) for the treatment of unresectabl
 e hepatocellular carcinoma (uHCC).  Key considerations in choosing a treat
 ment option for these cancers will also be discussed.\n\n 
DTSTART:20260304T163000Z
DTEND:20260304T172000Z
LAST-MODIFIED:20260905T021254Z
LOCATION:
SEQUENCE:0
STATUS:CONFIRMED
SUMMARY:Product Theater: Treatment Approaches for Resectable Gastric / Gast
 roesophageal Junction Cancers or Unresectable Hepatocellular Carcinoma
TRANSP:OPAQUE
X-ALT-DESC;FMTTYPE=text/html:<p><span style='font-size:12pt\;'><span style=
 'font-family:Aptos\, sans-serif\;'><span style='font-size:11pt\;'>This pre
 sentation discusses perioperative IMFINZI (durvalumab) in combination with
  FLOT (fluorouracil\, leucovorin\, oxaliplatin and docetaxel)\, followed b
 y adjuvant IMFINZI alone\, for the treatment of resectable gastric or gast
 roesophageal junction adenocarcinoma (GC/GEJC)\, along with IMFINZI + IMJU
 DO (tremelimumab-actl) for the treatment of unresectable hepatocellular ca
 rcinoma (uHCC).  Key considerations in choosing a treatment option for the
 se cancers will also be discussed.</span></span></span></p>\n\n<p> </p>
BEGIN:VALARM
UID:64353337-3565-4732-b336-653563646361
ACTION:DISPLAY
DESCRIPTION:This presentation discusses perioperative IMFINZI (durvalumab) 
 in combination with FLOT (fluorouracil\, leucovorin\, oxaliplatin and doce
 taxel)\, followed by adjuvant IMFINZI alone\, for the treatment of resecta
 ble gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)\, along 
 with IMFINZI + IMJUDO (tremelimumab-actl) for the treatment of unresectabl
 e hepatocellular carcinoma (uHCC).  Key considerations in choosing a treat
 ment option for these cancers will also be discussed.\n\n 
TRIGGER:-PT15M
END:VALARM
END:VEVENT
END:VCALENDAR